Clinical Trial Update: Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating cadonilimab in non-squamous non-small cell lung cancer patients resistant to EGFR-TKI.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cadonilimab

Snippet

Sponsor: Guangzhou University of Traditional Chinese Medicine | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN